Japanese Regulators Approve Promega CDx for Merck's Keytruda

Feb 05, 2019

|

NEW YORK (GenomeWeb) — Promega announced today that Japan's Ministry of Health, Labour, and Welfare has approved a companion diagnostic for Merck's cancer immunotherapy Keytruda (pembrolizumab) based on its microsatellite instability (MSI) technology.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Japanese Regulators Approve Promega CDx for Merck's Keytruda

To read the full story....

Breaking News

Randox Laboratories Invests $33.7M to Increase Coronavirus Testing Capacity

Roche Garners FDA Emergency Use Authorization for Elecsys IL-6 Test in COVID-19 Patients

Immunovia Raises $43.0M Through Stock Issuance

Eurofins Technologies Nabs CE Mark for Coronavirus Total Antibody Test

FDA Issues Emergency Use Authorizations for Gravity Diagnostics, Aspirus, CSI Coronavirus Tests

OpGen Expands Partnership With New York State Department of Health to Detect AMR Infections

Featured White Papers

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

What's Popular?

Beset by COVID-19 Pandemic, Europe Searches for Right Test Mix for Diagnosis, Surveillance

Roche Garners FDA Emergency Use Authorization for Elecsys IL-6 Test in COVID-19 Patients

At-Home Coronavirus Tests Get Nod From FDA But Agency Proceeding With Caution

FDA Issues Emergency Use Authorizations for Gravity Diagnostics, Aspirus, CSI Coronavirus Tests

Randox Laboratories Invests $33.7M to Increase Coronavirus Testing Capacity

Sponsorships